These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 26278391)

  • 21. Lipidomic signature of serum from the rats exposed to alcohol for one year.
    Li H; Xu W; Jiang L; Gu H; Li M; Zhang J; Guo W; Deng P; Long H; Bu Q; Tian J; Zhao Y; Cen X
    Toxicol Lett; 2018 Sep; 294():166-176. PubMed ID: 29758358
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD).
    Musso G; Gambino R; Cassader M
    Prog Lipid Res; 2009 Jan; 48(1):1-26. PubMed ID: 18824034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipidomics reveals a remarkable diversity of lipids in human plasma.
    Quehenberger O; Armando AM; Brown AH; Milne SB; Myers DS; Merrill AH; Bandyopadhyay S; Jones KN; Kelly S; Shaner RL; Sullards CM; Wang E; Murphy RC; Barkley RM; Leiker TJ; Raetz CR; Guan Z; Laird GM; Six DA; Russell DW; McDonald JG; Subramaniam S; Fahy E; Dennis EA
    J Lipid Res; 2010 Nov; 51(11):3299-305. PubMed ID: 20671299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
    Tessari P; Coracina A; Cosma A; Tiengo A
    Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis.
    Yetukuri L; Katajamaa M; Medina-Gomez G; Seppänen-Laakso T; Vidal-Puig A; Oresic M
    BMC Syst Biol; 2007 Feb; 1():12. PubMed ID: 17408502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of miR-155 in the liver of transgenic mice alters the expression profiling of hepatic genes associated with lipid metabolism.
    Lin X; Jia J; Du T; Li W; Wang X; Wei J; Lin X; Zeng H; Yao L; Chen X; Zhuang J; Weng J; Liu Y; Lin J; Wu Q; Wang W; Yao K; Xu K; Xiao D
    PLoS One; 2015; 10(3):e0118417. PubMed ID: 25799309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A theoretical study of lipid accumulation in the liver-implications for nonalcoholic fatty liver disease.
    Schleicher J; Guthke R; Dahmen U; Dirsch O; Holzhuetter HG; Schuster S
    Biochim Biophys Acta; 2014 Jan; 1841(1):62-9. PubMed ID: 23999488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver lipid metabolism.
    Nguyen P; Leray V; Diez M; Serisier S; Le Bloc'h J; Siliart B; Dumon H
    J Anim Physiol Anim Nutr (Berl); 2008 Jun; 92(3):272-83. PubMed ID: 18477307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Untargeted lipidomics reveals lipid metabolism disorders induced by oxathiapiprolin in Phytophthora sojae.
    Liu X; Li C; Chen Y; Xue Z; Miao J; Liu X
    Pest Manag Sci; 2023 Apr; 79(4):1593-1603. PubMed ID: 36562252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipidomics Reveals a Tissue-Specific Fingerprint.
    Pradas I; Huynh K; Cabré R; Ayala V; Meikle PJ; Jové M; Pamplona R
    Front Physiol; 2018; 9():1165. PubMed ID: 30210358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrative Lipidomics and Metabolomics for System-Level Understanding of the Metabolic Syndrome in Long-Term Treated HIV-Infected Individuals.
    Olund Villumsen S; Benfeitas R; Knudsen AD; Gelpi M; Høgh J; Thomsen MT; Murray D; Ullum H; Neogi U; Nielsen SD
    Front Immunol; 2021; 12():742736. PubMed ID: 35095835
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of lipid-supplemented total parenteral nutrition on fatty liver disease in a premature neonatal piglet model.
    Hyde MJ; Amusquivar E; Laws J; Corson AM; Geering RR; Lean IJ; Putet G; Dodds PF; Herrera E; Clarke L
    Neonatology; 2008; 93(2):77-86. PubMed ID: 17684422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanism of hepatic steatosis: pathophysiological role of autophagy.
    Wang K
    Expert Rev Mol Med; 2016 Aug; 18():e14. PubMed ID: 27499351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of lipid metabolism in the pathogenesis of alcoholic and nonalcoholic hepatic steatosis.
    Sozio MS; Liangpunsakul S; Crabb D
    Semin Liver Dis; 2010 Nov; 30(4):378-90. PubMed ID: 20960377
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Untargeted lipidomics based on UPLC-QTOF-MS/MS and structural characterization reveals dramatic compositional changes in serum and renal lipids in mice with glyoxylate-induced nephrolithiasis.
    Chao Y; Gao S; Wang X; Li N; Zhao H; Wen X; Lou Z; Dong X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Sep; 1095():258-266. PubMed ID: 30099286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notch1 deficiency decreases hepatic lipid accumulation by induction of fatty acid oxidation.
    Song NJ; Yun UJ; Yang S; Wu C; Seo CR; Gwon AR; Baik SH; Choi Y; Choi BY; Bahn G; Kim S; Kwon SM; Park JS; Baek SH; Park TJ; Yoon K; Kim BJ; Mattson MP; Lee SJ; Jo DG; Park KW
    Sci Rep; 2016 Jan; 6():19377. PubMed ID: 26786165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
    Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
    Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.